-
this paper shows that the decreased expression of activating receptor NKp30 on peripheral blood NK cells is positively associated with gastric cancer progression
-
Low NKp30 expression on NK cells is associated with Nasopharyngeal Carcinoma.
-
we propose NKp30 status as a simple and early prognostic biomarker that identifies intermediate-risk patients with poor prognosis who otherwise may not be identified with existing risk stratification systems.
-
Data indicate a sequence of events driven by tumour-derived prostaglandin D2 (PGD2) associated with engagement of the natural cytotoxicity triggering receptor 3 (NKp30)-B7H6 antigen (B7H6) pathway leading to significant group 2 innate lymphoid cells (ILC2s) activation and expansion.
-
NKp44 and NKp30 splice variants profiles are tissue/condition specific and demonstrate similarity between placenta and cancerous tissues.
-
Results found that rs2736191-C NCR3 carriers had a significant increased number of mild malaria episodes compared to the non-carriers. This SNP had a significantly increased promoter activity in NCR33 gene and involves a binding site for STAT4 and RUNX3.
-
findings show HIV reservoir size is dependent on the presence of a defined NK cell population with a specific transcriptional signature: high NCR (NKp46 and NKp30) and IFN-gamma inducibility upon NCR and cytokine receptor engagement
-
Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells
-
Data suggest that NK cells and NKp30 could play a role in Antisynthetase syndrome pathogenesis.
-
the stalk domains of NKp30 and NKp46, another NCR employing CD3zeta for signaling, were not exchangeable without drastic deficiencies in folding, plasma membrane targeting, and/or ligand-induced receptor signaling.
-
Age and CMV serostatus influence the expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated natural killer cells.
-
NKp30-B7-H6 interaction is a novel cell contact mechanism that mediates activation of Group 2 innate lymphoid cells and identifies a potential target for the development of novel therapeutics for atopic dermatitis and other atopic diseases.
-
Our results suggest that NKP30-B7-H6 interaction can aggravate hepatocyte damage, probably through up-regulation of IL-32 expression in hepatitis B virus-related acute-on-chronic liver failure
-
the interaction between NKp30 and B7-H6 may contribute to the fate of neuroblastoma patients
-
Suggest role for NKp30 isoforms in influencing liver damage and ensuing fibrosis in chronic hepatitis C infection.
-
show that in addition to NKG2D, human CEACAM1 can inhibit NK-cell activation via NKp30 or 2B4
-
Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasms.
-
Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
-
Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
-
NKp30 was required for natural killer cell-fungal conjugate formation, phosphatidylinositol 3-kinase (PI3K) signaling, and perforin release.
